当前位置: X-MOL 学术Clin. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime
Clinical Infectious Diseases ( IF 11.8 ) Pub Date : 2020-04-01 , DOI: 10.1093/cid/ciaa355
Ryan K Shields 1, 2 , Alina Iovleva 1 , Ellen G Kline 1 , Akito Kawai 3, 4 , Christi L McElheny 1 , Yohei Doi 1, 2, 3, 4
Affiliation  

We report 2 independent patients from whom carbapenem and ceftazidime-avibactam–resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2–amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.

中文翻译:

暴露于头孢吡肟的阴沟肠杆菌复合物中AmpC介导的头孢他啶-阿维巴坦和头孢地洛尔耐药的临床演变

我们报告了2名独立患者,他们从中鉴定出了碳青霉烯和头孢他啶-阿维巴坦耐药的阴沟肠杆菌复杂菌株。头孢他啶-avibactam耐药性归因于AmpCβ-内酰胺酶R2环中的2个氨基酸缺失,同时引起对头孢吡肟的耐药性并降低了对头孢吡罗(一种新型铁载体头孢菌素)的敏感性。
更新日期:2020-04-01
down
wechat
bug